Last reviewed · How we verify
Epidoxorubicin — Competitive Intelligence Brief
phase 2
Tyrosine-protein kinase Fyn, 5-hydroxytryptamine receptor 4, Genome polyprotein
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Epidoxorubicin (Epidoxorubicin) — Hoffmann-La Roche.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Epidoxorubicin TARGET | Epidoxorubicin | Hoffmann-La Roche | phase 2 | Tyrosine-protein kinase Fyn, 5-hydroxytryptamine receptor 4, Genome polyprotein |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Epidoxorubicin CI watch — RSS
- Epidoxorubicin CI watch — Atom
- Epidoxorubicin CI watch — JSON
- Epidoxorubicin alone — RSS
Cite this brief
Drug Landscape (2026). Epidoxorubicin — Competitive Intelligence Brief. https://druglandscape.com/ci/epidoxorubicin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing